Analysis of a multi-component multi-stage malaria vaccine candidate-tackling the cocktail challenge

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Boes, Alexander ^a   Spiegel, Holger ^a   Voepel, Nadja ^a   Edgue, Gueven ^a   Beiss, Veronique ^a   Kapelski, Stephanie ^a   Fendel, Rolf ^a,b   Scheuermayer, Matthias ^c   Pradel, Gabriele ^b   Bolscher, Judith M ^d   Behet, Marije C ^e   Dechering, Koen J ^d   Hermsen, Cornelus C ^e   Sauerwein, Robert W ^d,e   Schillberg, Stefan ^a   Reimann, Andreas ^a   Fischer, Rainer ^a,b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Zentrum für Infektionsforschung ^*  (Germany)

^d Current affiliation: TropIQ Health Sciences   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IMMUNIZATION; IN VITRO STUDY; LIVER CELL; NEUTROPHIL; NICOTIANA BENTHAMIANA; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; RABBIT; ANIMAL; BLOOD; IMMUNOLOGY; MALARIA, FALCIPARUM;

ORYCTOLAGUS CUNICULUS; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIBODIES, PROTOZOAN; IMMUNIZATION; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RABBITS;

EID: 84940434878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131456     Document Type: Article

References (58)

1. Organization WH. Ld Malaria Report 2012. World Health Organization. 2013;(1pp).
2. Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M, et al. Safety and Immunogenicity of the Synthetic Malaria Vaccine Spf66 in a Large Field Trial. Journal of Infectious Diseases. 1992; 166 (1):139-44. PMID: WOS:A1992HZ74600020.
3. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013; 341(6152):1359-65. doi: 10.1126/science.1241800 PMID: 23929949.
4. Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol. 2001; 31(8):753-62. PMID: 11403765.
5. Hill AVS, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, et al. Prime-boost vectored malaria vaccines Progress and prospects. Human vaccines. 2010; 6(1):78-83. PMID: WOS:000274650200010.
6. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. The New England journal of medicine. 1997; 336(2):86-91. Epub 1997/01/09. doi: 10.1056/NEJM199701093360202 PMID: 8988885.
7. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against bloodstage malaria. Infect Immun. 2002; 70(12):6961-7. doi: 10.1128/Iai.70.12.6961-6967.2002 PMID: WOS:000179377600057.
8. Faber BW, Younis S, Remarque EJ, Garcia RR, Riasat V, Walraven V, et al. Diversity Covering AMA1-MSP1(19) Fusion Proteins as Malaria Vaccines. Infect Immun. 2013; 81(5):1479-90. doi: 10.1128/Iai. 01267-12 PMID: WOS:000317582700011.
9. Pan WQ, Huang DQ, Zhang QF, Qu L, Zhang DM, Zhang XL, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. Journal of immunology. 2004; 172(10):6167-74. PMID: WOS:000221276900049.
10. Zhou ZY, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, et al. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Human vaccines. 2006; 2(1):14-23. PMID: WOS:000243916900003.
11. Hill AVS. Vaccines against malaria. Philos T R Soc B. 2011; 366(1579):2806-14. doi: 10.1098/rstb. 2011.0091 PMID: WOS:000294553600011.
12. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. The New England journal of medicine. 2011; 365(20):1863-75. Epub 2011/10/20. doi: 10.1056/NEJMoa1102287 PMID: 22007715.
13. Saul A, Fay MP. Human Immunity and the Design of Multi-Component, Single Target Vaccines. PloS one. 2007; 2(9). doi: ARTN e850 doi: 10.1371/journal.pone.0000850 PMID: WOS:000207455500033.
14. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature. 2002; 418(6899):785-9. doi: 10.1038/Nature00937 PMID: WOS:000177428000041.
15. Bathurst IC, Gibson HL, Kansopon J, Hahm BK, Green KM, Chang SP, et al. An Experimental Vaccine Cocktail for Plasmodium-Falciparum Malaria. Vaccine. 1993; 11(4):449-56. doi: 10.1016/0264-410x (93)90287-8 PMID: WOS:A1993KR21400011.
16. Plassmeyer ML, Reiter K, Shimp RL, Kotova S, Smith PD, Hurt DE, et al. Structure of the Plasmodium falciparum Circumsporozoite Protein, a Leading Malaria Vaccine Candidate. Journal of Biological Chemistry. 2009; 284(39):26951-63. doi: 10.1074/jbc.M109.013706 PMID: WOS:000269969600075.
17. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(17):9952-7. doi: 10.1073/ pnas.1633254100 PMID: WOS:000184926000060.
18. Kariu T, Ishino T, Yano K, Chinzei Y, Yuda M. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol. 2006; 59(5):1369-79. doi: 10.1111/j.1365-2958. 2958.2005.05024.x PMID: WOS:000235220200002.
19. Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, et al. Immunization with Pre-Erythrocytic Antigen CelTOS from Plasmodium falciparum Elicits Cross-Species Protection against Heterologous Challenge with Plasmodium berghei. PloS one. 2010; 5(8). doi: ARTN e12294 doi: 10.1371/journal.pone.0012294 PMID: WOS:000281075500022.
20. Morahan BJ, Wang L, Coppel RL. No TRAP, no invasion. Trends in parasitology. 2009; 25(2):77-84. doi: 10.1016/J.Pt.2008.11.004 PMID: WOS:000263774400008.
21. Blackman MJ, Heidrich HG, Donachie S, Mcbride JS, Holder AA. A Single Fragment of a Malaria Merozoite Surface Protein Remains on the Parasite during Red-Cell Invasion and Is the Target of Invasion-Inhibiting Antibodies. Journal of Experimental Medicine. 1990; 172(1):379-82. doi: 10.1084/jem.172.1.379 PMID: WOS:A1990DL09100047.
22. Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends in parasitology. 2008; 24(2):74-84. doi: 10.1016/j.pt.2007.12.002 PMID: 18226584.
23. Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun. 2001; 69(7):4390-7. doi: 10.1128/IAI.69.7.4390-4397.2001 PMID: 11401978; PubMed Central PMCID: PMC98511.
24. Alaro JR, Angov E, Lopez AM, Zhou H, Long CA, Burns JM. Evaluation of the Immunogenicity and Vaccine Potential of Recombinant Plasmodium falciparum Merozoite Surface Protein 8. Infect Immun. 2012; 80(7):2473-84. doi: 10.1128/Iai.00211-12 PMID: WOS:000305599400023.
25. Oeuvray C, Bouharountayoun H, Grasmasse H, Bottius E, Kaidoh T, Aikawa M, et al. Merozoite Surface Protein-3-a Malaria Protein Inducing Antibodies That Promote Plasmodium-Falciparum Killing by Cooperation with Blood Monocytes. Blood. 1994; 84(5):1594-602. PMID: WOS:A1994PE38700030.
26. Kaslow DC, Isaacs SN, Quakyi IA, Gwadz RW, Moss B, Keister DB. Induction of Plasmodium-Falciparum Transmission-Blocking Antibodies by Recombinant Vaccinia Virus. Science. 1991; 252 (5010):1310-3. doi: 10.1126/science.1925544 PMID: WOS:A1991FN85700041.
27. Williamson KC, Keister DB, Muratova O, Kaslow DC. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Molecular and biochemical parasitology. 1995; 75(1):33-42. doi: 10.1016/0166-6851(95)02507-3 PMID: WOS:A1995TQ60500004.
28. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol Journal. 2010; 8(5):620-37. Epub 2010/03/18. doi: 10.1111/j.1467-7652.2010.00507.x PMID: 20233333.
29. Fischer R, Schillberg S, Buyel JF, Twyman RM. Commercial aspects of pharmaceutical protein production in plants. Current pharmaceutical design. 2013; 19(31):5471-7. Epub 2013/02/12. PMID: 23394566.
30. Boes A, Spiegel H, Edgue G, Kapelski S, Scheuermayer M, Fendel R, et al. Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits. Plant Biotechnol Journal. 2015; 13(2):222-34. doi: 10.1111/pbi.12255 PMID: 25236489.
31. Voepel N, Boes A, Edgue G, Beiss V, Kapelski S, Reimann A, et al. Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants. Biotechnol J. 2014; 9(11):1435-45. doi: 10.1002/biot.201400350 PMID: WOS:000344542600008.
32. Beiss V, Spiegel H, Boes A, Kapelski S, Scheuermayer M, Edgue G, et al. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein. Biotechnology and bioengineering. 2015; 112(7):1297-305. doi: 10.1002/bit.25548 PMID: 25615702.
33. Pol E, Karlsson R, Roos H, Jansson A, Xu B, Larsson A, et al. Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma. Journal of molecular recognition: JMR. 2007; 20(1):22-31. Epub 2006/10/13. doi: 10.1002/jmr.804 PMID: 17036306.
34. Behet MC, Foquet L, van Gemert GJ, Bijker EM, Meuleman P, Leroux-Roels G, et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malaria journal. 2014; 13. doi: Artn 136 doi: 10.1186/1475-2875-13-136 PMID: WOS:000334810000001.
35. van Schaijk BC, Janse CJ, van Gemert GJ, van Dijk MR, Gego A, Franetich JF, et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PloS one. 2008; 3(10):e3549. doi: 10.1371/journal.pone.0003549 PMID: 18958160; PubMed Central PMCID: PMC2568858.
36. Kapelski S, Klockenbring T, Fischer R, Barth S, Fendel R. Assessment of the neutrophilic antibodydependent respiratory burst (ADRB) response to Plasmodium falciparum. Journal of leukocyte biology. 2014; 96(6):1131-42. doi: 10.1189/jlb.4A0614-283RR PMID: 25118179; PubMed Central PMCID: PMC4226792.
37. Bishop A, Gilchrist BM. Experiments upon the feeding of Aëdes aegypti through animal membranes with a view to applying this method to the chemotherapy of malaria. Parasitology. 1946; 37(1-2):85-100. doi: 10.1017/S0031182000013202
38. Feller T, Thom P, Koch N, Spiegel H, Addai-Mensah O, Fischer R, et al. Plant-based production of recombinant Plasmodium surface protein pf38 and evaluation of its potential as a vaccine candidate. PloS one. 2013; 8(11):e79920. Epub 2013/11/28. doi: 10.1371/journal.pone.0079920 PMID: 24278216; PubMed Central PMCID: PMC3836784.
39. Gregory JA, Li FW, Tomosada LM, Cox CJ, Topol AB, Vinetz JM, et al. Algae-Produced Pfs25 Elicits Antibodies That Inhibit Malaria Transmission. PloS one. 2012; 7(5). doi: ARTN e37179 doi: 10.1371/ journal.pone.0037179 PMID: WOS:000305341300083.
40. Farrance CE, Chichester JA, Musiychuk K, Shamloul M, Rhee A, Manceva SD, et al. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum Vaccines. 2011; 7 Suppl:191-8. Epub 2011/01/27. PMID: 21266847.
41. Farrance CE, Rhee A, Jones RM, Musiychuk K, Shamloul M, Sharma S, et al. A Plant-Produced Pfs230 Vaccine Candidate Blocks Transmission of Plasmodium falciparum. Clin Vaccine Immunol. 2011; 18(8):1351-7. doi: 10.1128/Cvi.05105-11 PMID: WOS:000293352100020.
42. Tachibana M, Wu YM, Iriko H, Muratova O, MacDonald NJ, Sattabongkot J, et al. N-Terminal Prodomain of Pfs230 Synthesized Using a Cell-Free System Is Sufficient To Induce Complement-Dependent Malaria Transmission-Blocking Activity. Clin Vaccine Immunol. 2011; 18(8):1343-50. doi: 10.1128/Cvi. 05104-11 PMID: WOS:000293352100019.
43. Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Molecular and biochemical parasitology. 1994; 67(1):59-68. Epub 1994/09/01. PMID: 7838184.
44. Drew DR, Sanders PR, Crabb BS. Plasmodium falciparum merozoite surface protein 8 is a ring-stage membrane protein that localizes to the parasitophorous vacuole of infected erythrocytes. Infect Immun. 2005; 73(7):3912-22. doi: 10.1128/Iai.73.7.3912-3922.2005 PMID: WOS:000230151100011.
45. Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. Journal of Biological Chemistry. 2005; 280(44):37236-45. doi: 10.1074/jbc.M506753200 PMID: WOS:000232901800082.
46. Kapelski S, Boes A, Spiegel H, de Almeida M, Klockenbring T, Reimann A, et al. Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody. Malaria journal. 2015; 14. doi: Artn 50 doi: 10.1186/S12936-015-0577-7 PMID: WOS:000349129800002.
47. Boyle MJ, Richards JS, Gilson PR, Chai W, Beeson JG. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood. 2010; 115(22):4559-68. doi: 10. 1182/blood-2009-09-243725 PMID: 20220119.
48. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002; 70(6):3101-10. PMID: 12011004; PubMed Central PMCID: PMC127972.
49. Mahajan B, Berzofsky JA, Boykins RA, Majam V, Zheng H, Chattopadhyay R, et al. Multiple Antigen Peptide Vaccines against Plasmodium falciparum Malaria. Infect Immun. 2010; 78(11):4613-24. doi: 10.1128/Iai.00533-10 PMID: WOS:000283052100018.
50. Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo. Infect Immun. 2000; 68(6):3667-73. PMID: 10816526; PubMed Central PMCID: PMC97657.
51. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. Journal of Experimental Medicine. 2011; 208(2):341-56. doi: 10.1084/Jem.20101488 PMID: WOS:000287366300011.
52. Bergmann-Leitner ES, Li Q, Caridha D, O'Neil MT, Ockenhouse CF, Hickman M, et al. Protective immune mechanisms against pre-erythrocytic forms of Plasmodium berghei depend on the target antigen. Trials in Vaccinology. 2014; 3(0):6-10. http://dx.doi.org/10.1016/j.trivac.2013.11.002.
53. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malaria journal. 2009; 8:312. doi: 10.1186/1475-2875-8-312 PMID: 20042088; PubMed Central PMCID: PMC2806383.
54. Chappel JA, Egan AF, Riley EM, Druilhe P, Holder AA. Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro. Infect Immun. 1994; 62(10):4488-94. PMID: 7927713; PubMed Central PMCID: PMC303134.
55. Kumar S, Collins W, Egan A, Yadava A, Garraud O, Blackman MJ, et al. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun. 2000; 68 (4):2215-23. doi: 10.1128/Iai.68.4.2215-2223.2000 PMID: WOS:000086010300063.
56. Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clinical and vaccine immunology: CVI. 2009; 16(7):963-8. Epub 2009/05/15. doi: 10.1128/CVI.00042-09 PMID: 19439523; PubMed Central PMCID: PMC2708396.
57. Jones RM, Chichester JA, Mett V, Jaje J, Tottey S, Manceva S, et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PloS one. 2013; 8(11):e79538. doi: 10.1371/journal.pone.0079538 PMID: 24260245; PubMed Central PMCID: PMC3832600.
58. Cheru L, Wu Y, Diouf A, Moretz SE, Muratova OV, Song G, et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine. 2010; 28(27):4423-9. doi: 10.1016/j. vaccine.2010.04.036 PMID: 20434549; PubMed Central PMCID: PMC2880321.